| Identification | Back Directory | [Name]
APIGENIN-6-ARABINOSIDE-8-GLUCOSIDE | [CAS]
52012-29-0 | [Synonyms]
Isoshaftoside
apigenin-6-α-L-arabinosyl-8-β-glucoside
6-C-alpha-L-Arabinosyl-8-C-beta-D-glucosylapigenin
Apigenin 6-C-alpha-L-arabinopyranoside-8-C-beta-D-glucopyranoside
4H-1-Benzopyran-4-one, 6-α-L-arabinopyranosyl-8-β-D-glucopyranosyl-5,7-dihydroxy-2-(4-hydroxyphenyl)-
5,7-dihydroxy-2-(4-hydroR)-3,4,5-trihydroxy-6-(hydroxR,4S,5S)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl]-4H-chromen-4-one (non-preferred name)
5,7-dihydroxy-2-(4-hydroxyphenyl)-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]-6-[(2S,3R,4S,5S)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl]-4H-chromen-4-one (non-preferred name) | [EINECS(EC#)]
218-362-5 | [Molecular Formula]
C26H28O14 | [MDL Number]
MFCD00210518 | [MOL File]
52012-29-0.mol | [Molecular Weight]
564.49 |
| Chemical Properties | Back Directory | [Boiling point ]
935.0±65.0 °C(Predicted) | [density ]
1.766 | [solubility ]
Soluble in ethanol and methanol; | [form ]
powder | [pka]
5.70±0.40(Predicted) | [color ]
Orange | [Water Solubility ]
sparingly soluble in water | [InChIKey]
NKVFUCSDZNNOHZ-JOAYLRBINA-N | [SMILES]
C1(C2=CC=C(O)C=C2)OC2=C(C(=C(OC3OC[C@@H](O)[C@@H](O)[C@@H]3O)C(=C2OC2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)O)O)C(=O)C=1 |&1:17,19,21,28,31,33,35,r| | [LogP]
0.040 (est) |
| Hazard Information | Back Directory | [Chemical Properties]
White crystalline powder, soluble in organic solvents such as methanol, ethanol, DMSO, etc., derived from Desmodium sibiricum, Herba Lysimachiae, and Herba Camelliae Preparata. | [Uses]
food and beverages | [Definition]
ChEBI: A C-glycosyl compound that is apigenin substituted at positions 6 and 8 by alpha-L-arabinopyranosyl and beta-D-glucosyl residues respectively. | [in vivo]
Isoschaftoside (20 mg/kg; i.p.; daily for 4 weeks) reverses the nonalcoholic fatty liver disease (NAFLD) and reduces hepatic steatosis in mice[3].
| Animal Model: | C57 mice fed with a high-fat diet (HFD) (4 weeks; male; C57BL/6JGpt)[3] | | Dosage: | 20 mg/kg | | Administration: | Intraperitoneal injection (i.p.); daily for 4 weeks | | Result: | Significantly reduced the body weight and body size of the high-fat diet mice compared with the model group.
Reduced the visceral fat weight of high-fat diet mice.
Significantly attenuated hepatic lipid accumulation induced by a high-fat diet and decreased the number of intracellular lipid droplets and hepatocyte balloons.
Reversed the damage to liver function and the elevation of blood glucose caused by a high-fat diet.
The expression level of p62 and LC3-II was significantly lower than that in the HFD group.
|
|
|
|